In this edition:
Pembrolizumab + radiotherapy in frail, newly diagnosed, early-stage natural killer/T-cell lymphoma
POLARGO: Pola-R-GemOx vs. R-GemOx in ASCT-ineligible R/R DLBCL
STARGLO: 2-year analysis of Glofit-GemOx vs. R-GemOx in R/R DLBCL
A novel prognostication index for early-stage classic Hodgkin lymphoma
Real-world Canadian patient outcomes in the DA-EPOCH-R era
NIVEAU: nivolumab + GemOx in transplant-ineligible R/R PTCL
LOTIS-7: loncastuximab tesirine + glofitamab in R/R DLBCL
MARIETTA: MATRix/RICE induction & thiotepa ASCT in secondary CNS lymphoma
EPCORE DLBCL-3: fixed-duration epcoritamab in older, anthracycline-ineligible, treatment-naïve LBCL
A novel CD19/CD20 bi-specific CAR T-cell therapy in R/R LBCL
Please login below to download this issue (PDF)